According to the relationship described, when might hormone therapy not increase CAD risk?

According to the relationship described, when might hormone therapy not increase CAD risk?

• A. MHT increases CAD risk in all ages
• B. MHT may not increase CAD risk if started between ages 50 and 59 with less than 10 years since menopause onset
• C. There is no relation between menopause and CAD
• D. MHT decreases CAD risk irrespective of age

Answer: (B)

The main idea is that the cardiovascular effects of menopausal hormone therapy depend on when it’s started relative to menopause. When hormone therapy is begun in the early postmenopausal period—roughly within the first decade after menopause and around ages 50 to 59—the risk of developing coronary artery disease may be neutral or not increased. This aligns with the “timing hypothesis,” which suggests estrogen’s effects on the blood vessels can be more favorable soon after menopause, potentially improving endothelial function and lipid profiles while avoiding harm seen in later years or longer time since menopause. So the statement that hormone therapy may not raise CAD risk if started in that early window best reflects this timing-based understanding. In contrast, starting therapy later after menopause or at older ages is not consistently associated with no risk and can even increase CAD risk in some scenarios, and the other choices ignore the important role of timing or overstate the protective effect across all ages.

The main idea is that the cardiovascular effects of menopausal hormone therapy depend on when it’s started relative to menopause. When hormone therapy is begun in the early postmenopausal period—roughly within the first decade after menopause and around ages 50 to 59—the risk of developing coronary artery disease may be neutral or not increased. This aligns with the “timing hypothesis,” which suggests estrogen’s effects on the blood vessels can be more favorable soon after menopause, potentially improving endothelial function and lipid profiles while avoiding harm seen in later years or longer time since menopause.

So the statement that hormone therapy may not raise CAD risk if started in that early window best reflects this timing-based understanding. In contrast, starting therapy later after menopause or at older ages is not consistently associated with no risk and can even increase CAD risk in some scenarios, and the other choices ignore the important role of timing or overstate the protective effect across all ages.